

1 **NATIONAL INSTITUTE FOR HEALTH AND CARE**
2 **EXCELLENCE**

3 **Guideline**

4 **Cerebral palsy in adults**

5 **Draft for consultation, July 2018**
6

This guideline covers care and support for adults with cerebral palsy. It focuses on recognising, assessing and managing muscle tone as well as common complications and comorbidities. It also covers improving participation and service organisation. It aims to improve the health and wellbeing of adults with cerebral palsy.

NICE has also produced guidelines on [cerebral palsy in under 25s: assessment and management](#) and [spasticity in under 19s: management](#).

Who is it for?

- Healthcare professionals from primary and secondary care
- Social care practitioners and professionals from other sectors, such as non-governmental, education and voluntary organisations
- People responsible for planning services, commissioners and providers
- Adults with cerebral palsy their families and carers

This draft guideline contains:

- the draft recommendations
- recommendations for research
- rationale and impact sections that explain why the committee made the recommendations and how they might affect practice
- the guideline context.

Information about how the guideline was developed is on the [guideline's page](#) on the NICE website. This includes the evidence reviews, the scope, and details of the committee and any declarations of interest.

1

2

1 Contents

| | | |
|----|--------------------------------------------------------------------------------|----|
| 2 | Contents..... | 3 |
| 3 | Recommendations | 4 |
| 4 | 1.1 Service organisation..... | 4 |
| 5 | 1.2 Function and participation | 7 |
| 6 | 1.3 Managing abnormal muscle tone | 11 |
| 7 | 1.4 Assessment and monitoring of clinical complications and comorbidities..... | 18 |
| 8 | Terms used in this guideline | 27 |
| 9 | Recommendations for research | 29 |
| 10 | Rationale and impact..... | 30 |
| 11 | Context..... | 59 |
| 12 | Finding more information and resources | 60 |
| 13 | | |

1 Recommendations

People have the right to be involved in discussions and make informed decisions about their care, as described in [your care](#).

[Making decisions using NICE guidelines](#) explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.

2 **1.1 Service organisation**

3 **Moving into adults' services**

4 1.1.1 For young adults moving from children's to adults' services, ensure that
5 transitions to adult services are managed in line with the NICE guidelines
6 on [cerebral palsy in under 25s](#) and [transition from children's to adults'
7 services for young people using health or social care services](#).

8 **Access to services**

9 1.1.2 Refer adults with cerebral palsy to a multidisciplinary team experienced in
10 the management of neurological impairments if:

- 11 • their ability to carry out their usual daily activities deteriorates **or**
- 12 • a neurosurgical or orthopaedic procedure is being considered that may
- 13 affect their ability to carry out their usual daily activities.

14 1.1.3 Recognise that reassessment by the multidisciplinary team and different
15 clinical services may be needed by adults with cerebral palsy to ensure
16 that their care meets their changing needs at different points in their lives.

17 1.1.4 Commissioners and service providers should develop pathways that allow
18 adults with cerebral palsy access to a local network of care that includes:

- 19 • advocacy support
- 20 • learning disability services

- 1 • mental health services
 - 2 • orthopaedic surgery (and post-surgery rehabilitation)
 - 3 • [rehabilitation engineering services](#)
 - 4 • rehabilitation medicine or specialist neurology services
 - 5 • secondary care expertise for managing comorbidities (for example,
 - 6 respiratory, gastrointestinal and urology services)
 - 7 • social care
 - 8 • specialist therapy services (for example physiotherapy and
 - 9 occupational therapy)
 - 10 • wheelchair services.
- 11 1.1.5 Ensure that adults with cerebral palsy, their families and carers, and their
- 12 primary care teams are provided with information about their local network
- 13 of specialist services.
- 14 1.1.6 Explain to the person with cerebral palsy and their family members and
- 15 carers their right to a care and support needs assessment, in line with the
- 16 [Care Act 2014](#), and discuss with them the type of support available.
- 17 1.1.7 Recognise and address barriers to accessing primary and secondary care
- 18 for adults with cerebral palsy. These may include:
- 19 • personal barriers, such as:
 - 20 – communication difficulties between the adult and healthcare
 - 21 professionals
 - 22 – mental health-related factors such as depression, anxiety
 - 23 – lack of an advocate (for example, a family member, carer or friend) if
 - 24 needed
 - 25 – social and emotional factors such as fear of stigma, lack of
 - 26 motivation and exhaustion
 - 27 • physical barriers, such as:
 - 28 – inadequate physical access to buildings
 - 29 – difficulties with transport
 - 30 • organisational barriers, such as:

- 1 – lack of availability of appropriate equipment (for example, hoists and
2 wheelchair weighing scales) and adequate changing and toilet
3 facilities
4 – inadequate time given in appointments, for example, to allow for
5 hoisting and dressing.

6 1.1.8 When an adult with cerebral palsy is admitted to hospital, the staff should
7 always offer advocacy, health and personal care (toileting, washing,
8 nutrition and hydration) even if the person has a family member, carer or
9 advocate there to support them.

10 1.1.9 Provide information about national screening services (for example
11 breast, colon and cervical cancer screening) to adults with cerebral palsy.

To find out why the committee made recommendations on moving into adults' services and access to services and how they might affect practice, see [rationale and impact](#).

12 **Ongoing care**

13 1.1.10 Consider regular reviews for adults with cerebral palsy, tailored to their
14 needs and preferences. Agree with the person the frequency of review
15 and which services should be involved based on their needs and
16 preferences.

17 1.1.11 Offer an annual review of the person's clinical and functional needs,
18 carried out by a member of the clinical team, for people with cerebral
19 palsy who have complex needs (such as GMFCS levels IV and V) and
20 any of the following:

- 21 • with communication difficulties
- 22 • with learning disabilities
- 23 • in long-term care settings
- 24 • living in the community without sufficient practical and social support
25 (for example, being cared for by elderly, frail parents)
- 26 • with multiple comorbidities.

- 1 1.1.12 Discuss with the person with cerebral palsy (and their family and carers, if
2 agreed) what information should inform the regular or annual review, and
3 who should receive clinical information following review (for example their
4 GP).
- 5 1.1.13 Record details of the person's review and share the information with
6 relevant people (for example healthcare professionals and social care
7 practitioners), with the person's permission.
- 8 1.1.14 Discuss with the person with cerebral palsy (and their family and carers, if
9 agreed) who will be their main point of contact between reviews.
- 10 1.1.15 If an adult with cerebral palsy chooses not to have regular reviews, offer
11 the person (and their family and carers, if agreed) information on when to
12 contact a healthcare professional and how to access the specialist
13 services that they may need. Ensure that the person's GP and
14 multidisciplinary team are aware that they do not want to be reviewed
15 regularly (with the person's permission).
- 16 1.1.16 For adults with cerebral palsy and learning disabilities, offer an annual
17 health check in primary care (see NHS England's [information on annual](#)
18 [health checks](#) and NICE's guidelines on [care and support of people](#)
19 [growing older with learning disabilities](#) and [challenging behaviour and](#)
20 [learning disabilities](#)). Ensure that a referral to specialist services is made if
21 a need for this is identified.

To find out why the committee made recommendations on ongoing care and how they might affect practice, see [rationale and impact](#).

22

23 **1.2 Function and participation**

24 **Communication**

- 25 1.2.1 Be aware that speech and communication needs in adults with cerebral
26 palsy may change with time and social circumstances.

- 1 1.2.2 At every review, ask adults with cerebral palsy (and their families and
2 carers, if agreed) about any changes in their hearing, speech and
3 communication.
- 4 1.2.3 Explore with the person with cerebral palsy who has communication
5 difficulties whether they have a potential need for [alternative and](#)
6 [augmentative communication systems](#).
- 7 1.2.4 Be aware that adults with cerebral palsy and poor intelligibility of speech
8 may still prefer to use speech as their main means of communication.
- 9 1.2.5 Refer adults with cerebral palsy who have communication difficulties to
10 speech therapy services to assess their need for:
- 11 • alternative or augmentative communication systems **or**
12 • intensive speech therapy to improve their speech or expressive
13 language.
- 14 1.2.6 Ensure that training is provided for people with cerebral palsy using
15 alternative and augmentative communication systems and their families,
16 carers and other [key communication partners](#) in home, care, social or
17 work environments.
- 18 1.2.7 See also NICE's guideline on [patient experience in adult NHS services](#) for
19 general advice on how to provide information and communicate with
20 adults receiving care.

To find out why the committee made the recommendations on communication and how they might affect practice, see [rationale and impact](#).

21 **Vocational and independent living skills**

- 22 1.2.8 Recognise and address external factors that prevent people with cerebral
23 palsy from participating in activities, including:
- 24 • environmental barriers, for example access to buildings
25 • social barriers, for example carers with unmet training needs

- 1 • institutional barriers, for example policies and situations that put people
2 with cerebral palsy at a disadvantage.
- 3 1.2.9 If adults with cerebral palsy have complex physical, cognitive, language or
4 sensory needs, consider offering referral to occupational therapy services
5 to assess the person’s functional needs and provide individualised
6 support.
- 7 1.2.10 Give adults with cerebral palsy information about assessments of
8 vocational and independent living skills that is tailored to the person’s
9 functional abilities and goals (see NICE’s guideline on [patient experience
10 in adult NHS services for advice on information giving](#) and NICE’s
11 guideline on [people’s experience in adult social care service](#) for advice
12 and information provision).
- 13 1.2.11 If an adult with cerebral palsy finds it difficult to participate in a chosen
14 activity, assess their physical and mental health and address any factors
15 identified that may be affecting participation, if possible.
- 16 1.2.12 Refer adults with cerebral palsy who would like to work or live
17 independently, or who are already working, to a professional with
18 expertise in vocational and independent living skills. Give information and
19 advice, which could include:
- 20 • 'Access to work' schemes
21 • employment support to include workplace training and job retention
22 • leisure activities
23 • occupational health assessment or workplace assessment
24 • statutory welfare benefits
25 • supporting a planned exit from the workforce if it becomes too difficult
26 to continue working
27 • vocational rehabilitation
28 • voluntary work.
- 29 See also NICE’s guideline on [workplace health: management practices](#) for
30 advice on improving the health and wellbeing of employees.

To find out why the committee made the recommendations on vocational and independent living skills and how they might affect practice, see [rationale and impact](#).

1 **Electronic assistive technology**

2 1.2.13 Discuss with adults with cerebral palsy the potential need for [electronic](#)
3 [assistive technology](#) if they have problems with participation and
4 independence.

5 1.2.14 If adults with cerebral palsy have complex physical, cognitive, language or
6 sensory needs, consider referring them to services providing information,
7 assessment and provision of electronic assistive technology.

8 1.2.15 If adults with cerebral palsy are already using electronic assistive
9 technology, discuss at every review any:

- 10
- problems or concerns they have with their equipment
 - potential changes in their needs.
- 11

12 1.2.16 Be aware that using electronic assistive technology may mean that the
13 person with cerebral palsy needs less contact with their carers, which may
14 reduce their social interaction.

15 1.2.17 Ensure that training is provided for adults with cerebral palsy using
16 electronic assistive technology, and for their families or carers, if
17 appropriate.

To find out why the committee made the recommendations on electronic assistive technology and how they might affect practice, see [rationale and impact](#).

18 **Physical activity**

19 1.2.18 Discuss with adults with cerebral palsy (and their families or carers, if
20 agreed) the importance of physical activity in maintaining general fitness
21 and physical and mental health.

1 1.2.19 Provide information on local services that support people with cerebral
2 palsy to take part in physical activity.

3 1.2.20 Consider referring people with cerebral palsy to services with experience
4 and expertise in neurological impairments that can provide support with
5 physical activities (including sport) and tasks of daily living. Depending on
6 local service provision and the person's needs, this may be to one of the
7 following services:

- 8 • physiotherapy
- 9 • occupational therapy
- 10 • rehabilitation engineering services
- 11 • wheelchair services.

12 **Orthopaedic surgery**

13 1.2.21 If participation in physical activities is limited by pain or joint problems that
14 do not respond to any other treatments, consider referring the person to a
15 musculoskeletal specialist or an orthopaedic surgeon with experience and
16 expertise in managing musculoskeletal problems in adults with cerebral
17 palsy.

To find out why the committee made the recommendations on physical activity and how they might affect practice, see [rationale and impact](#).

18 **1.3 Managing abnormal muscle tone**

19 **Agreeing goals for treatment**

20 1.3.1 When considering any treatments for spasticity or dystonia, discuss with
21 the adult with cerebral palsy (and their family and carers, if agreed):

- 22 • treatment goals (and document them) **and**
- 23 • the benefits and risks of treatments (for example, the risk of
24 deterioration in function) as part of their multidisciplinary treatment
25 strategy.

1 For further information on supporting people to actively participate in their
2 care and shared decision-making see [NICE's guideline on patient](#)
3 [experience in adult NHS services](#).

4 **Initial management of spasticity and dystonia**

5 1.3.2 Be aware that adults with cerebral palsy may have both spasticity and
6 dystonia. The severity of symptoms for both conditions may fluctuate in
7 response to health, social and emotional wellbeing, and environmental
8 factors.

9 1.3.3 At every [review](#) discuss with the person with cerebral palsy (and their
10 family and carers, if agreed) factors that may exacerbate their spasticity or
11 dystonia, such as:

- 12 • bladder problems (for example, urinary tract infection or bladder
- 13 stones)
- 14 • constipation
- 15 • emotional distress
- 16 • pain
- 17 • posture
- 18 • pressure sores
- 19 • changes in home or work environments, including seating
- 20 • medication changes and side effects.

21 1.3.4 Address any modifiable factors identified that may be exacerbating
22 spasticity or dystonia before discussing further management options with
23 the adult with cerebral palsy.

24 1.3.5 Discuss with the person with cerebral palsy (and their family and carers, if
25 agreed) the balance between the benefits and harms of treating spasticity
26 and dystonia. In particular, explain that some people use their spasticity or
27 dystonia to help their posture and ability to stand, walk or transfer, and
28 that treatment may affect this.

To find out why the committee made the recommendations on agreeing goals for treatment and initial management of spasticity and dystonia, and how they might affect practice, see [rationale and impact](#).

1

2 **Spasticity**

3 **Enteral muscle relaxant drug¹ treatments**

4 1.3.6 Consider enteral baclofen¹ as the first-line drug treatment for adults with
5 cerebral palsy and generalised spasticity causing:

- 6 • functional impairment **or**
- 7 • pain **or**
- 8 • spasms.

9 1.3.7 Start enteral baclofen¹ treatment with a low dose and increase the dose
10 gradually over about 4 weeks to achieve the optimum therapeutic effect.

11 1.3.8 If enteral baclofen¹ is ineffective or not tolerated by adults with cerebral
12 palsy and generalised spasticity:

- 13 • refer the person to a tone or spasticity management service **or**
- 14 • discuss other drug treatment options (including other enteral muscle
15 relaxants) with a tone management specialist.

16 1.3.9 Do not offer diazepam for spasticity in adults with cerebral palsy, except in
17 an acute situation when spasticity is causing severe pain or anxiety.

18 1.3.10 Do not rapidly withdraw muscle relaxant drugs if the adult with cerebral
19 palsy has been taking them for more than a few weeks. Reduce the dose
20 gradually to avoid withdrawal symptoms.

¹ At the time of consultation (July 2018) oral formulations of muscle relaxant drugs are usually not licensed to be given via an enteral feeding tube so administration via this route would be off-label. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

1 ***Botulinum toxin type A injections***

2 1.3.11 Consider referring adults with cerebral palsy for botulinum toxin type A
3 treatment if:

- 4
- 5 • they have spasticity in a limited number of muscle groups that is:
 - 6 – affecting their care (such as hygiene or dressing) **or**
 - 7 – causing pain **or**
 - 8 – impairing activity and participation, **or**
 - 9 • a tone management specialist agrees that treatment targeted to focal muscle groups is likely to improve their function and symptoms.

| |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>To find out why the committee made the recommendations on drug treatments for spasticity, and how they might affect practice, see rationale and impact.</p> |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

10 ***Neurosurgical treatments to reduce spasticity***

11 **Intrathecal baclofen**

12 1.3.12 Consider referring adults with cerebral palsy to a tone or spasticity
13 management service offering continuous pump-administered intrathecal
14 baclofen therapy if they still have difficulties with spasticity, despite enteral
15 muscle relaxant drug treatment or botulinum toxin type A treatment.

16 1.3.13 When considering continuous pump-administered intrathecal baclofen,
17 give the person (and their family and carers, if agreed) information and
18 discuss the procedure with them. This should include:

- 19
- 20 • the need for an intrathecal baclofen test to ensure treatment is suitable
 - 21 • the surgical procedure for implanting the pump
 - 22 • the need for regular hospital follow-up visits to ensure optimal dosage and pump refill
 - 23 • the risks of implanting a pump and pump-related complications (for
24 example battery failure or catheter leakage), which can result in
25 baclofen withdrawal or overdose
 - 26 • a [review of 24-hour postural needs](#).

1 1.3.14 If continuous pump-administered intrathecal baclofen is being considered
2 for an adult with cerebral palsy, perform an intrathecal baclofen test to
3 assess if it is suitable before implanting a pump. This should involve:

- 4 • a test dose or doses of intrathecal baclofen given to the person by
5 lumbar puncture **or**
- 6 • a test dose or doses of intrathecal baclofen given to the person through
7 a spinal catheter.

8 1.3.15 Assess the effect of the test dose or doses of intrathecal baclofen on:

- 9 • reducing increased muscle tone
- 10 • reducing pain
- 11 • reducing the frequency of muscle spasms
- 12 • motor function, such as sitting, standing, walking.

13 1.3.16 Discuss with the adult with cerebral palsy (and their family and carers, if
14 agreed) their views on the response to the intrathecal baclofen test.

15 **Selective dorsal rhizotomy**

16 1.3.17 Only consider selective dorsal rhizotomy for adults with cerebral palsy and
17 spasticity after they have been assessed by a multidisciplinary team with:

- 18 • specialist training and expertise in the care of spasticity **and**
- 19 • access to the full range of treatment options.

20 See also NICE interventional procedure guidance on [selective dorsal](#)
21 [rhizotomy for spasticity in cerebral palsy](#).

22 1.3.18 When considering selective dorsal rhizotomy, give the person (and their
23 family and carers, if agreed) information and discuss the impact of the
24 procedure with them. This should include:

- 25 • that the procedure cannot be reversed
- 26 • the possible complications
- 27 • the need for prolonged physiotherapy and aftercare

- 1 • the possible impact on function
- 2 • that the long-term benefits are uncertain.

To find out why the committee made the recommendations on neurosurgical treatments to reduce spasticity, and how they might affect practice, see [rationale and impact](#).

3

4 **Dystonia**

- 5 1.3.19 Refer adults with cerebral palsy and problematic dystonia (for example,
6 causing problems with function, pain or participation) to a tone or
7 spasticity management service to consider treatment options.

8 **Enteral anti-dystonic drug² treatments**

- 9 1.3.20 Do not prescribe levodopa³ to manage dystonia in adults with cerebral
10 palsy, except in the rare situation when it is used for a therapeutic trial in
11 dopa-responsive dystonia.

- 12 1.3.21 Do not rapidly withdraw enteral drugs for treating dystonia if the person
13 has been taking them for more than a few weeks. Reduce the dosage
14 gradually to avoid withdrawal symptoms.

15 ***Botulinum toxin type A injections***

- 16 1.3.22 Only consider botulinum toxin type A⁴ treatment for focal dystonia in
17 adults with cerebral palsy when:

² At the time of consultation (July 2018) oral formulations of anti-dystonic drugs are usually not licensed to be given via an enteral feeding tube so administration via this route would be off-label. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

³ At the time of consultation (July 2018), levodopa did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

⁴ At the time of consultation (July 2018), botulinum toxin type A did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

- 1 • the person is under the supervision of a tone or spasticity management
2 service, and it is part of a wider programme of therapy **and**
3 • local dystonia is:
4 – affecting their care (such as hygiene or dressing), **or**
5 – causing pain **or**
6 – impairing activity and participation.
- 7 1.3.23 When considering botulinum toxin type A⁵ treatment, take into account
8 and explain to the adult with cerebral palsy (and their family and carers, if
9 agreed):
- 10 • that the severity and pattern of dystonia may change after treatment
11 **and**
12 • the potential impact of treatment on function.

To find out why the committee made the recommendations on drug treatments for dystonia, and how they might affect practice, see [rationale and impact](#).

13

14 ***Neurosurgical treatment to reduce dystonia***

15 **Intrathecal baclofen**

- 16 1.3.24 Only consider continuous pump-administered intrathecal baclofen⁶ if
17 people with cerebral palsy still have difficulties with dystonia, despite
18 having enteral anti-dystonic drug treatment or botulinum toxin type A⁵
19 treatment. Provide information and discuss the procedure, including

⁵ At the time of consultation (July 2018), botulinum toxin type A did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

⁶ Although intrathecal baclofen is licensed in UK clinical practice for severe spasticity, at the time of consultation (July 2018) it did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

1 intrathecal baclofen testing, with the person (and their family or carer, if
2 agreed) as described in recommendations 1.3.13 to 1.3.16.

3 **Deep brain stimulation**

4 1.3.25 If adults with cerebral palsy continue to have severe and painful dystonia,
5 despite having enteral anti-dystonic drug treatment or botulinum toxin type
6 A treatment, consider referring them to a specialised centre with
7 experience in providing deep brain stimulation. See also NICE
8 interventional procedure guidance on [deep brain stimulation for tremor
9 and dystonia \(excluding Parkinson's disease\)](#).

To find out why the committee made the recommendations on treatments for
dystonia, and how they might affect practice, see [rationale and impact](#).

10

11 **1.4 Assessment and monitoring of clinical complications** 12 **and comorbidities**

13 **Bone and joint disorders**

14 1.4.1 Discuss with adults with cerebral palsy (and their families or carers, if
15 agreed) that:

- 16 • their musculoskeletal function may deteriorate gradually, and any
17 changes should be investigated to identify treatable causes
- 18 • early recognition of bone and joint disorders enables early treatment,
19 which may improve outcomes.

20 **Osteoporosis and fracture risk**

21 1.4.2 Be aware that low bone mineral density is common in adults with cerebral
22 palsy, particularly in people:

- 23 • with reduced mobility or reduced weight bearing
- 24 • taking anticonvulsants or proton pump inhibitors
- 25 • who have had a previous low-impact fracture.

1 1.4.3 Consider assessing for risk of fractures secondary to osteoporosis in
2 adults with cerebral palsy. Risk factors to assess include:

- 3 • needing help with moving or having to be moved, for example hoisting
- 4 • history of falls
- 5 • low BMI
- 6 • history of low-impact fractures
- 7 • other medical factors, for example steroid use, that may adversely
- 8 affect bone health.

9 For more information about assessment of fracture risk, see NICE's
10 guideline on [osteoporosis: assessing the risk of fragility fracture](#).

11 1.4.4 Consider a dual-energy X-ray absorptiometry (DXA) assessment in adults
12 with cerebral palsy who have 2 or more risk factors (see recommendation
13 1.2.3), particularly if they have had a previous low-impact fracture.

14 1.4.5 Consider referring adults with cerebral palsy for specialist assessment
15 and management, for example, to a rheumatology, endocrinology or bone
16 health service, if they have:

- 17 • a high fracture risk **or**
- 18 • a positive DXA result.

19 ***Disorders caused by abnormal musculoskeletal development***

20 1.4.6 Be aware that, because of abnormal musculoskeletal development, adults
21 with cerebral palsy are more likely to have bone and joint disorders.

22 1.4.7 Refer adults with cerebral palsy to a specialist orthopaedic or
23 musculoskeletal service if a bone or joint disorder is suspected and
24 causing pain or affecting posture or function. These may include:

- 25 • osteoarthritis
- 26 • cervical instability or spondylosis
- 27 • spinal deformity (including scoliosis, kyphosis and lordosis)
- 28 • subluxation of the hips, wrist and shoulders

- 1 • biomechanical knee problems
 - 2 • abnormalities of the foot structure.
- 3 1.4.8 Do not offer an X-ray to assess for hip subluxation or curvature of the
- 4 spine in adults with cerebral palsy, unless the person is in pain or their
- 5 posture or function is affected.

To find out why the committee made the recommendations on bone and joint disorders, and how they might affect practice, see [rationale and impact](#).

6 **Mental health problems**

- 7 1.4.9 Identify and address mental health problems alongside physical health
- 8 problems. Recognise that the impact of mental health problems and
- 9 emotional difficulties can be as important as physical health problems for
- 10 adults with cerebral palsy.
- 11 1.4.10 Follow NICE guidelines on identifying and managing specific mental
- 12 health problems, and psychological and neurodevelopmental disorders in
- 13 adults who have cerebral palsy, for example:
- 14 • [attention deficit hyperactivity disorder](#)
 - 15 • [depression in adults](#) and [depression in adults with a chronic physical](#)
 - 16 [health problem](#)
 - 17 • [generalised anxiety disorder and panic disorder in adults](#).
 - 18 • [autism spectrum disorder in adults](#)
 - 19 • [challenging behaviour and learning disabilities](#)
 - 20 • [mental health problems in people with learning disabilities](#).
- 21 1.4.11 Tailor the identification and assessment of mental health problems and
- 22 emotional difficulties to the needs and abilities of the person, in particular
- 23 take into account communication difficulties or learning disabilities.
- 24 1.4.12 At every review explore with the adult with cerebral palsy (and their family
- 25 and carers, if agreed) if they have any concerns about, for example, their:
- 26 • mood

- 1 • irritability
- 2 • behaviour
- 3 • social interaction
- 4 • general level of function.

5 1.4.13 Involve families and carers, when agreed, in identifying and assessing
6 mental health problems and emotional difficulties in adults with cerebral
7 palsy.

8 1.4.14 Take into account the specific factors that might affect the identifying,
9 assessing and managing mental health problems and emotional
10 difficulties in people with cerebral palsy. These may include:

- 11 • adverse effects of medicines (including the effects of medicines used
12 for managing mental health problems on motor function or those used
13 for managing motor function on mental health)
- 14 • communication difficulties
- 15 • learning disabilities
- 16 • impaired neuropsychological and [executive function](#)
- 17 • comorbidities, particularly epilepsy and pain
- 18 • side effects and drug interactions of multiple medicines
19 (polypharmacy).

20 1.4.15 Discuss with the adult with cerebral palsy (and their family and carers, if
21 agreed) if physical problems, such as pain, or frustration from
22 communication difficulties or lack of stimulation are contributing to
23 emotional distress or challenging behaviour.

To find out why the committee made the recommendations on mental health problems, and how they might affect practice, see [rationale and impact](#).

24 **Difficulties with eating and nutritional problems**

25 1.4.16 Offer adults with cerebral palsy a regular weight check and BMI
26 evaluation, and identify people who may be at risk of undernutrition or

- 1 obesity (see also the NICE guideline on [obesity: identification,](#)
2 [assessment and management](#)).
- 3 1.4.17 At every review, discuss with adults with cerebral palsy (and their family
4 and carers, if agreed) whether they have difficulties with eating or there
5 have been any changes in their eating habits. Ask about issues including:
- 6 • changes in appetite
7 • changes in the person's ability to feed themselves
8 • coughing or choking when eating
9 • food refusal
10 • increased frequency of chest infections (which may be related to
11 swallowing difficulties or gastro-oesophageal reflux)
12 • an increase in the length of meal times.
- 13 1.4.18 Discuss if any of the following factors might be affecting the person's
14 appetite, eating habits or weight:
- 15 • changes in carer support
16 • pain and depression
17 • reduced physical activity
18 • side effects of medications.
- 19 1.4.19 Be aware that adults with cerebral palsy with severe spasticity and
20 dyskinesia may have an increased metabolic rate and a higher risk of
21 malnutrition.
- 22 1.4.20 Follow the recommendations on screening for malnutrition, indications for
23 nutrition support, and education and training of staff and carers related to
24 nutrition in NICE's guideline on [nutrition support for adults](#).
- 25 1.4.21 Refer adults with cerebral palsy to a relevant clinical specialist if
26 assessment suggests they have difficulties with eating or malnutrition.

To find out why the committee made the recommendations on difficulties with eating and nutritional problems, and how they might affect practice, see [rationale and impact](#).

1 **Respiratory disorders**

2 ***Identifying and monitoring respiratory disorders***

3 1.4.22 Be aware that adults with cerebral palsy are at increased risk of
4 respiratory failure. Symptoms may include:

- 5 • breathlessness
- 6 • changes in behaviour (such as irritability or inability to concentrate)
- 7 • daytime drowsiness
- 8 • worsening epilepsy
- 9 • headaches on waking
- 10 • increasing frequency of chest infections
- 11 • poor sleep pattern
- 12 • sleep apnoea.

13 1.4.23 Recognise that some risk factors for respiratory impairment are more
14 common in adults with severe cerebral palsy (Gross Motor Function
15 Classification System [GMFCS] level IV or V), such as:

- 16 • aspiration pneumonia
- 17 • chronic cardio-respiratory disorders (for example, cor pulmonale or
18 pulmonary circulation hypertension)
- 19 • chronic suppurative lung disease
- 20 • kyphoscoliosis
- 21 • poor saliva control
- 22 • recurrent chest infections.

23 1.4.24 Refer adults with cerebral palsy and persistent or multiple signs and
24 symptoms of respiratory impairment, or risk factors for respiratory
25 impairment (see recommendations 1.2.22 and 1.2.23) to specialist
26 services.

- 1 1.4.25 Consider assessment with spirometry for adults with cerebral palsy who
2 are suspected to be at high risk of respiratory impairment.

To find out why the committee made the recommendations on identifying and monitoring respiratory disorders, and how they might affect practice, see [rationale and impact](#).

3

4 ***Prophylactic treatments for respiratory infections***

- 5 1.4.26 Offer vaccinations to adults with cerebral palsy and their carers, in line
6 with the national immunisation programme (see the [Green book](#) for further
7 information).

- 8 1.4.27 Do not offer prophylactic antibiotics for respiratory infections in adults with
9 cerebral palsy, unless:

- 10 • the person is at high risk of respiratory infection (see recommendation
11 1.2.23) **and**
12 • they are offered on the advice of a respiratory specialist with expertise
13 in neurodisability management.

- 14 1.4.28 If an adult with cerebral palsy is at high risk of respiratory infection,
15 consider a prophylactic physiotherapy chest care review. This may
16 include:

- 17 • postural management
18 • advice on exercise
19 • advice on training and care for family members and carers.

- 20 1.4.29 Refer adults with cerebral palsy and recurrent chest infections, if
21 dysphagia is suspected, to a speech and language therapist with training
22 in dysphagia to assess swallowing.

To find out why the committee made the recommendations on prophylactic treatments for respiratory disorders, and how they might affect practice, see [rationale and impact](#).

1 ***Discussing the management of respiratory failure***

2 1.4.30 If a person with cerebral palsy has symptoms of respiratory failure, or is at
3 high risk of developing respiratory failure, discuss their management plan
4 with them (and their family or carers if agreed), including:

- 5
- 6 • assessing the effectiveness and tolerability of treatment
 - 7 • treatment goals and [escalation plan](#) of treatment
 - 8 • managing complications
 - options for managing progressive respiratory failure.

9 ***Assisted ventilation for respiratory failure***

10 1.4.31 Consider home-based non-invasive ventilation for adults with cerebral
11 palsy and respiratory failure.

12 1.4.32 If a person is having home-based non-invasive ventilation, carry out a
13 review with a multidisciplinary team every 3 to 6 months. Assess and
14 discuss with the person (and their family and carers, if agreed) the
15 effectiveness, tolerability and whether agreed goals are being met.

16 1.4.33 Discuss with the person having non-invasive ventilation (and their family
17 or carers, if agreed) their preferences for future treatment. Agree a plan
18 for what should happen if an intercurrent infection (occurring during the
19 progress of respiratory failure) causes an acute deterioration in respiratory
20 function and record this in the person's [advance care plan](#).

21 1.4.34 If the person's agreed treatment goals are not met by non-invasive
22 ventilation, consider alternative treatment options such as tracheostomy
23 or [supportive care](#), taking into account the person's preferences for future
24 treatment (see recommendation 1.4.33).

1 **Assisted ventilation for sleep apnoea**

- 2 1.4.35 If an adult with cerebral palsy has sleep apnoea follow the advice in the
3 NICE technology appraisal guidance on [continuous positive airway](#)
4 [pressure for the treatment of obstructive sleep apnoea/hypopnoea](#)
5 [syndrome](#).

To find out why the committee made the recommendations on discussing the management of respiratory failure, and assisted ventilation for respiratory failure and sleep apnoea, and how they might affect practice, see [rationale and impact](#).

6 **Pain**

- 7 1.4.36 Be aware that some adults with cerebral palsy have difficulty
8 communicating, or are unable to communicate, that they are in pain.
- 9 1.4.37 Assess for the presence, severity and location of pain in adults with
10 cerebral palsy using pain assessment tools such as:
- 11 • numerical rating scales
 - 12 • visual analogue scales
 - 13 • faces pain scales
 - 14 • body maps.
- 15 1.4.38 If an adult with cerebral palsy has difficulty communicating:
- 16 • discuss with their family or carers how best to identify pain and include
17 this information in their care plan
 - 18 • use observational or descriptive pain scales to assess the presence,
19 severity and location of pain.
- 20 See also NICE's guideline on [patient experience in adult NHS services](#) for
21 advice on communication.
- 22 1.4.39 Ensure that health and social care staff (and families and carers, if
23 appropriate) caring for adults with cerebral palsy have access to a range
24 of pain assessment tools and that they have been trained in their use.

To find out why the committee made the recommendations on pain, and how they might affect practice, see [rationale and impact](#).

1

2 ***Terms used in this guideline***

3 **Advance care plan**

4 Defined by international consensus as ‘A process that supports adults at any age or
5 stage of health in understanding and sharing their personal values, life goals, and
6 preferences about future medical care. The goal of an advance care plan is to help
7 ensure that people receive medical care that is consistent with their values, goals
8 and preferences during serious and chronic illness.’ (Sudore et al [2017] [Defining
9 advance care planning for adults](#)).

10 **Alternative and augmentative communication systems**

11 Alternative and augmentative communication systems are a variety of methods (for
12 example signing, use of visual symbols and eye gaze technology) that can be used
13 to help people with disabilities communicate with others. These systems or methods
14 of communications can be used as an alternative to speech or to supplement it.

15 **Electronic assistive technology**

16 Any piece of equipment, or system, that is electronically powered (mains electricity
17 and/or battery), with the purpose to increase, maintain, or improve function of
18 individuals with disabilities. These may include communication aids, environmental
19 controls and access to computers.

20 **Enteral drug treatment**

21 Drugs given by mouth (oral), via a naso-gastric tube, gastrostomy tube or
22 jejunostomy tube.

23 **Escalation plan**

24 A record of the interventions that a person would find acceptable, in line with their
25 values, goals and preferences. It can be used to indicate that more intensive or
26 invasive interventions would be unacceptable to the person. For example, an
27 escalation plan of ward-based care only, indicates that the person would not want

1 invasive monitoring, intubation and ventilation, which are undertaken as part of
2 intensive care.

3 **Executive functions**

4 Cognitive processes that are important for the control of behaviour. These include
5 planning, organising and monitoring behaviours leading to goal attainment, inhibitory
6 control, working memory and cognitive flexibility. As a result of injuries to the frontal
7 lobes of the brain these processes can be disrupted.

8 **Gross Motor Function Classification System (GMFCS)**

9 A 5-level clinical classification system that describes the gross motor function of
10 people with cerebral palsy based on self-initiated movement abilities. People
11 assessed as level I are the most able and people assessed as level V are dependent
12 on others for all their mobility needs.

13 **Key communication partners**

14 People who regularly interact with the adult with cerebral palsy in any environment.
15 Communication may be by speech, using communication aids, signing, facial
16 expression or a combination of these.

17 **Rehabilitation engineering services**

18 Centres that design, develop and adapt technological solutions to overcome
19 challenges to function, activity and participation for individuals with disability. This
20 includes assessment and provision of assistive devices to help with posture, mobility
21 and communication (for example electronic assistive technology).

22 **Review**

23 A planned clinical appointment between an adult with cerebral palsy and a
24 healthcare professional. They may explore common concerns, physical symptoms,
25 mental health, pain, nutrition and communication to ensure an individualised
26 approach to care. The healthcare professional may be a GP, specialist nurse,
27 rehabilitation specialist or therapist. This allows also the opportunity to address
28 general health issues in the population as they grow older.

1 **Review of 24-hours postural needs**

2 Part of a 24-hour posture review that considers all the relevant postures that an
3 individual has the ability to adopt over the 24-hours of any given day. The 3 core
4 postural orientations are lying, sitting and standing. An example of a postural need is
5 support and positioning in bed.

6 **Supportive care**

7 Care focused on relieving symptoms caused by serious illnesses such as respiratory
8 failure. It can be given at any point during a person's illness to help them feel more
9 comfortable and improve their quality of life.

10 **Transferring**

11 Moving from one surface to another (for example, from a bed to a wheelchair)
12 independently or with assistance.

13 **Recommendations for research**

14 The guideline committee has made the following recommendations for research.

15 ***Key recommendations for research***

16 **1 Method of botulinum toxin type A injection in treating focal spasticity**

17 Is guided botulinum toxin type A injection using electrical localisation
18 (electrostimulation or electromyography) of muscles more effective and cost effective
19 than ultrasound-guided injections or clinical positioning for localisation of injections in
20 treating focal spasticity in adults with cerebral palsy?

21 To find out why the committee made the research recommendation on the method of
22 botulinum toxin type A injection in treating focal spasticity see [rationale and impact](#).

23 **2 Selective dorsal rhizotomy treatment to reduce spasticity**

24 What is the effectiveness and cost effectiveness of selective dorsal rhizotomy
25 compared with intrathecal baclofen to reduce spasticity in adults with cerebral palsy?

26 To find out why the committee made the research recommendation on selective
27 dorsal rhizotomy treatment to reduce spasticity see [rationale and impact](#).

1 **3 Detection and management of respiratory disorders in primary and**
2 **community care**

3 Can detection and management of respiratory disorder in adults with cerebral palsy
4 be improved in primary and community care?

5 To find out why the committee made the research recommendation on the detection
6 and management of respiratory disorders in primary and community care see
7 [rationale and impact](#).

8 **4 Prophylactic antibiotics for respiratory disorders**

9 Are prophylactic antibiotics effective and cost effective in the management of
10 respiratory symptoms in adults with cerebral palsy with significant respiratory
11 comorbidity?

12 To find out why the committee made the research recommendation on prophylactic
13 antibiotics for respiratory disorders see [rationale and impact](#).

14 **5 Splinting to improve or maintain posture or function**

15 What is the optimum regime for splints applied to the upper limb in adults with
16 cerebral palsy to improve or maintain posture or function?

17 To find out why the committee made the research recommendation on splinting to
18 improve or maintain posture or function see [rationale and impact](#).

19 **6 Augmentative and alternative communication systems**

20 Are augmentative and alternative communication systems effective and cost
21 effective in promoting communication for adults with cerebral palsy who have
22 communication difficulties?

23 To find out why the committee made the research recommendation on augmentative
24 and alternative communication systems see [rationale and impact](#).

25 **Rationale and impact**

26 These sections briefly explain why the committee made the recommendations and
27 how they might affect practice. They link to details of the evidence and a full
28 description of the committee's discussion.

1 ***Moving into adults' services and access to services***

2 Recommendations [1.1.1 to 1.1.9](#)

3 **Why the committee made the recommendations**

4 ***Moving into adults' services***

5 The committee discussed that specialist cerebral palsy services are provided for
6 children and young people, but there is insufficient specialist service provision for
7 adults, with variation and a lack of continuity in care. The committee highlighted that
8 it is important that services continue to meet the people's needs when they move
9 into adults' services, in line with recommendations in the NICE guidelines on
10 [cerebral palsy in under 25s](#) and [transition from children's to adults' services for](#)
11 [young people using health or social care services](#). To ensure that needs are met for
12 adults with cerebral palsy the committee made separate recommendations about
13 service organisations (see below).

14 ***Access to services***

15 Disabled people have the same rights to access healthcare services as other people.
16 These rights are outlined in the [Equality Act 2010](#) and the [UN Convention on the](#)
17 [rights of persons with disabilities](#). To support this, the committee highlighted that
18 there should be local pathways to enable access to a range of services for adults
19 with cerebral palsy. The committee agreed that referral to specialist services is
20 needed for some treatment options. Based on their discussions about treating
21 spasticity and dystonia (see evidence reviews A1, A2 and A3), the committee agreed
22 that access to specialist multidisciplinary teams is particularly important when a
23 person with cerebral palsy experiences a deterioration in their ability to carry out
24 usual daily activities, or when a neurosurgical or orthopaedic procedure is being
25 considered that may affect their abilities. Adults with cerebral palsy may also need
26 reassessment by the multidisciplinary team to take into account their changing needs
27 at different life stages. The committee highlighted this and to raise awareness that
28 people may need to access to different services if their needs change. These should
29 include access to a multidisciplinary team if the person's functional abilities
30 deteriorate or if the person's needs change.

1 The committee agreed that appropriate specialist services would need to be able to
2 address a wide variety of impairments and comorbidities, and that their needs are
3 likely to change at different stages of their life. To achieve good access to the
4 relevant specialists, local networks of care are needed. The committee also noted
5 that both people with cerebral palsy and healthcare professionals often lack
6 awareness of the services available. Based on their experience, they agreed that
7 provision of information about local networks of services would help to improve
8 access.

9 The committee also acknowledged that carers are often unaware of their right to a
10 local authority assessment of their own needs, including physical and mental health,
11 and to an assessment of their need for respite care under the [Care Act 2014](#). They
12 agreed that highlighting this would help carers to access support if needed.

13 The evidence showed that adults with cerebral palsy experience many obstacles to
14 equal access to services. Some of the barriers identified by the evidence are
15 highlighted in the recommendations to help raise awareness among healthcare
16 professionals. The committee agreed that healthcare professionals should ensure
17 that any barriers are addressed to enable equitable access to services and provide
18 timely care. This will improve quality of life and health outcomes for adults with
19 cerebral palsy.

20 The committee also noted that access to services may be limited for adults with
21 cerebral palsy who need practical support and advocacy. There was some evidence
22 that lack of an advocate could disadvantage people, especially when they are
23 admitted to hospital. The evidence also showed that some adults with cerebral palsy
24 reported that when they are admitted to hospital family members were expected to
25 act as their carers. The committee agreed that it should not be assumed that family
26 members should provide personal care in a healthcare setting and that advocacy
27 and health and personal care should always be offered to people when they are
28 admitted to hospital.

29 Based on their knowledge and experience, the committee noted inequalities in
30 access to national screening programmes for adults with cerebral palsy. They
31 agreed that increasing awareness would help to improve uptake of these services.

1 The committee acknowledged that there may be other barriers to screening, for
2 example providing breast screening for women in wheelchairs, especially those with
3 limited upper body strength, but they noted that interventions to improve screening
4 services was outside of the scope of the guideline.

5 **How the recommendations might affect practice**

6 The recommendations on access to services reinforce legislation and best current
7 practice.

8 Service organisation for networks of care is variable, so changes to practice will
9 depend on the availability of services within a particular local area. Providing
10 information about local networks of care may incur an initial cost to set-up.

11 There may be an increase in the number of referrals. Training will also be needed to
12 ensure healthcare professionals can manage referrals rapidly because there is a
13 limited number of healthcare professionals with expertise in neurological disorders.
14 However, recommendations with criteria for referral will help to reduce inappropriate
15 referrals and variations in referrals.

16 Full details of the evidence and the committee's discussion are [in evidence review](#)
17 [F1: Configuration of services for adults with cerebral palsy](#) and [evidence review F2:](#)
18 [Barriers to access to primary and secondary care](#).

19 [Return to recommendations](#)

20 **Ongoing care**

21 Recommendations [1.1.10 to 1.1.15](#)

22 **Why the committee made the recommendations**

23 There was limited evidence for the effectiveness of different service configurations.
24 One study suggested that fewer visits to emergency departments and hospital visits
25 were associated with having consistent outpatient care provided by a single doctor.
26 Although, the committee recognised that this may reflect the value of continuity of
27 care, they agreed that the quality of the evidence was not good enough to make a
28 recommendation.

1 Further evidence showed that changing the configuration of services to include the
2 time and staff for an annual review, could be cost-effective if there is a reduction of at
3 least 1 emergency department visit per year per person. It was not clear from the
4 evidence that this could be achieved when offered to all people with cerebral palsy.
5 The committee discussed the variation in the needs of people with cerebral palsy
6 and, based on their experience and knowledge, identified groups with more severe
7 or complex health and social care needs who would most benefit from being offered
8 an annual review. The evidence suggested annual review would be cost effective for
9 this group because they decided that this would on average prevent one emergency
10 department visit. It was noted that adults with learning disabilities should already be
11 offered an annual health check in primary care.

12 Although the evidence did not support annual reviews for all people with cerebral
13 palsy, the committee agreed that regular reviews are important to check for any new
14 problems and ensure that people's needs continue to be met. They agreed that
15 regular reviews should be considered, tailored to the person's needs. The frequency
16 of review was not specified because it will depend on person's needs and wishes.

17 It is important to discuss who should be involved in the review with the adult with
18 cerebral palsy. Information from different healthcare professionals and social care
19 staff may be essential to fully understand the person's clinical needs. Good record
20 keeping and sharing of information ensures that the outcome of the review is known
21 to all relevant people and that the appropriate actions are taken. The committee also
22 agreed that information about the review and any changes to the person's needs
23 should be shared to ensure integrated care.

24 To help maintain continuity of care between reviews, the committee agreed that
25 there should be a single point of contact, which could be a department or service in
26 primary or secondary care.

27 The committee recognised that some people may not need or wish to have regular
28 reviews. To ensure that they still have access specialist services when needed, the
29 committee agreed that they should be given information on how and when to do this.

1 **How the recommendations might affect practice**

2 Providing an annual review for adults with severe impairment will result in a minor
3 change in practice and reduce variation.

4 Many adults with severe impairments will already receive an annual health check in
5 accordance with the NICE guidelines on [care and support of people growing older](#)
6 [with learning disabilities](#) and [challenging behaviour and learning disabilities](#) and NHS
7 England's [information on annual health checks](#).

8 There may be bigger changes in practice for people with less severe impairment if
9 they are reviewed more often. However, the costs of this will be offset by the benefits
10 of more frequent checks, such as early identification and management of new
11 impairments or deterioration of function.

12 Full details of the evidence and the committee's discussion are in [evidence review](#)
13 [F1: Configuration of services for adults with cerebral palsy](#).

14 [Return to recommendations](#)

15 **Communication**

16 Recommendations [1.2.1 to 1.2.7](#)

17 **Why the committee made the recommendations**

18 There was limited evidence to support interventions to improve communication
19 between adults with cerebral palsy and their communication partners. However, the
20 committee acknowledged that communication is a basic human right and that adults
21 with cerebral palsy should be supported to communicate, express themselves and
22 live as independently as possible.

23 The committee was concerned that communication difficulties and changes to
24 communication needs are sometimes missed. Based on their experience, they
25 agreed that increased awareness of this and a check for any changes to speech,
26 hearing and communication at every review would help ensure that communication
27 needs are recognised.

1 There was some evidence that intensive speech therapy or supplemented speech
2 (using topic and alphabet cues) improved speech intelligibility, but the committee
3 agreed that it was not sufficient to recommend these specific interventions. However,
4 using this evidence and their knowledge and experience, the committee agreed that
5 referral to speech therapy services would enable adults with communication
6 difficulties to be assessed and offered suitable interventions.

7 Based on their experience and knowledge, the committee agreed that alternative
8 and augmentative communication systems may help some adults with cerebral palsy
9 to meet their communication needs, support independence and improve quality of
10 life and social relationships. Therefore the need for these systems should be
11 discussed with adults who have communication difficulties. The committee noted that
12 there is variation in the availability of training in these techniques, which is vital for
13 their effective use. They also highlighted that personal preference is important, and
14 that some people may not wish to use alternative or augmentative communication
15 systems in place of speech as their main means of communication.

16 The committee discussed that there was a need for more research on alternative
17 and augmentative communication systems. Current practice is to offer these
18 systems in preference to intensive speech and language therapy for people with
19 cerebral palsy and communication difficulties. However, there is only limited
20 evidence to support this in children with cerebral palsy and no evidence was
21 identified for adults. The committee developed a research recommendation to
22 determine the effectiveness of augmentative and alternative communication systems
23 in promoting communication for adults with cerebral palsy and communication
24 difficulties.

25 **How the recommendations might affect practice**

26 There is currently variation in practice and the recommendations will help to address
27 this and reinforce best practice.

28 Initially, an increase in referrals to speech therapy services and subsequent
29 management is likely. However this will decline as variations in practice are reduced.

30 There may be an increase in the use of augmentative and alternative communication
31 equipment, and related training, which will involve additional costs.

1 Full details of the evidence and the committee's discussion are in [evidence review](#)
2 [D4: Interventions to promote participation: communication](#).

3 [Return to recommendations](#)

4 ***Vocational and independent living skills***

5 Recommendations [1.2.8 to 1.2.12](#)

6 **Why the committee made the recommendations**

7 There was very little evidence on specific interventions for vocational or independent
8 living skills training. However, the committee acknowledged the benefits of increased
9 independence, social and occupational integration, participation in the community
10 and access to work for adults with cerebral palsy. Based on their experience and
11 knowledge, the committee agreed that people with problems participating in an
12 activity should have access to support. This should include assessing for and
13 addressing any barriers to participation and support, and may involve referral to
14 occupational therapy services, particularly for people with complex needs.

15 For adults who wish to work or live independently, the committee agreed that referral
16 for specialist support to access training, work placements and leisure activities would
17 be beneficial. Some evidence showed that people with higher educational attainment
18 and fewer physical complications were more likely to gain paid employment, but the
19 committee agreed that support should be an option regardless of ability, to enable all
20 adults to reach their full potential. For adults with cerebral palsy who are in work,
21 referral could support access to workplace and equipment assessment and
22 workplace and job retention training. The NICE guideline on [workplace health:](#)
23 [management practices](#) was highlighted by the committee as an important resource
24 to refer to.

25 The recommendations support compliance with the [Equality Act 2010](#) to protect
26 people from discrimination in employment, training and education. They also reflect
27 the fundamental rights of people with disabilities to independence, social and
28 occupational integration, participation in the community, access to training and to
29 engage in work, as set out in the [UN Convention on the rights of persons with](#)
30 [disabilities](#).

1 **How the recommendations might affect practice**

2 These recommendations are intended to reinforce good current practice, and
3 support government policy and legislation. Where they are not currently being
4 implemented, some services may need additional investment in resources.

5 Full details of the evidence and the committee's discussion are in [evidence review](#)
6 [D1: Interventions to promote participation: vocational and independent living skills](#).

7 [Return to recommendations](#)

8 ***Electronic assistive technology***

9 Recommendations [1.2.14 to 1.2.18](#)

10 **Why the committee made the recommendations**

11 There was no evidence identified on electronic assistive technology for adults with
12 cerebral palsy. Based on their experience, the committee agreed that adults with
13 cerebral palsy and complex disabilities would benefit from access to electronic
14 assisted technology, which may enhance their independence, quality of life and
15 improve their opportunities for employment. The recommendations support
16 legislation such as [The Human Rights Act 1998](#) and the [Equality Act 2010](#). The
17 recommendation on referral to services providing electronic assistive technology is
18 also in line with the NHS England [commissioning document on complex disability](#).

19 The committee was unable to recommend any specific electronic assistive
20 technology devices because of the lack of evidence. They agreed that services
21 providing electronic assistive technology should provide devices tailored to the
22 person's needs.

23 Variation in training and ongoing reviews of electronic assistive technology
24 equipment were highlighted by the committee. Training is important for both the adult
25 with cerebral palsy and their family and carers to ensure that the devices are used to
26 their full benefit. By discussing the use of their equipment at each review, the
27 healthcare professional can ensure that any problems with equipment or changes to
28 the person's needs are identified.

1 The committee noted that people using electronic assistive technology may need
2 less support from their carers and healthcare workers. This may reduce the person's
3 social contact, which can have a negative impact. Based on their experience, the
4 committee agreed that it is important that healthcare professionals take this into
5 account when discussing the risks and benefits of electronic assistive technology
6 with the adult with cerebral palsy, their family and carers.

7 **How the recommendations might affect practice**

8 These recommendations are intended to reinforce good current practice, and
9 support government policy and legislation. Where they are not currently being
10 implemented, some services may need additional investment in resources.

11 Full details of the evidence and the committee's discussion are in [evidence review](#)
12 [D3: Electronic assistive technology](#).

13 [Return to recommendations](#)

14 ***Physical activity, orthopaedic surgery and orthotics***

15 Recommendations [1.2.18 to 1.2.21](#)

16 **Why the committee made the recommendations**

17 ***Physical activity***

18 There was limited evidence on physical activity interventions for adults with cerebral
19 palsy, and what there was showed little or no improvements in, for example, mobility,
20 function and participation. However, based on their experience the committee
21 agreed that physical activity can help people with cerebral palsy with strength and
22 range of movement, as well as maintaining their general fitness and a healthy
23 weight. Evidence in the general population also shows that physical activity is of
24 benefit to people's overall health and wellbeing. The evidence did show that the risk
25 of injury or other adverse events for people with cerebral palsy was not increased by
26 doing physical activities such as strength training.

27 The committee agreed that physical activity should be promoted by providing
28 information and discussing the benefits with the adult with cerebral palsy. This would

1 also be in line with current government strategies for the wider population (for
2 example the [Start Active, Stay Active report](#) on physical activity in the UK).

3 Some adults with cerebral palsy may need extra support to overcome barriers to
4 participation in physical activities. Based on their experience, the committee agreed
5 that referral to a relevant service is likely to be helpful for some people; for example,
6 for assessment by a physiotherapist or occupational therapist to agree suitable
7 interventions. The recommendation also supports improved access to mobility aids,
8 including wheelchairs. The committee noted that a referral is in line with NHS
9 guidance on [choosing mobility equipment, wheelchairs and scooters](#) for people long-
10 term or permanent difficulty with mobility.

11 ***Orthopaedic surgery***

12 There was little evidence on orthopaedic surgery. However, the committee
13 recognised that some adults with cerebral palsy who have painful musculoskeletal
14 problems might benefit from surgery if other treatments are not effective. The
15 committee agreed that referral to an experienced orthopaedic surgeon could be
16 considered to review possible surgical options.

17 ***Orthotics***

18 There was no evidence identified on the effectiveness of orthotic devices for adults
19 with cerebral palsy. The committee discussed that there is variation in how orthoses
20 are used in current practice and decided that further research in this area is a
21 priority. Orthotic devices, such as splints, are used to help improve positioning and
22 function. They can be used alongside other treatments or separately. The committee
23 developed a research recommendation to determine the effectiveness of different
24 splinting regimens in improving and maintaining posture or functional abilities in the
25 upper limb.

26 **How the recommendations might affect practice**

27 The recommendations on interventions to maintain physical function reinforce
28 current best practice and should not lead to additional resource use. Any initial costs
29 of specialist advice would be outweighed by the potential savings from avoiding
30 complications, injuries and maintaining a wider range of abilities.

1 Full details of the evidence and the committee's discussion are in [evidence review](#)
2 [D2: Interventions that improve or maintain physical function and participation](#).

3 [Return to recommendations](#)

4 ***Agreeing goals for treatment and initial management of spasticity*** 5 ***and dystonia***

6 Recommendations [1.3.1 to 1.3.5](#)

7 **Why the committee made the recommendations**

8 The committee noted that there is a lack of understanding about the relationship
9 between spasticity and dystonia. Based on their experience, they agreed that a
10 better understanding of these conditions and the factors that affect them is likely to
11 lead to more effective decisions about management. They discussed factors that
12 commonly trigger or worsen symptoms of both spasticity and dystonia, and their
13 concerns that these may sometimes go unrecognised.

14 The committee also discussed the balance of benefits and risks of treatment to
15 reduce spasticity and dystonia. In particular, some people with cerebral palsy make
16 functional use of their increased muscle tone from spasticity and dystonia, for
17 example to help them walk or transfer independently. For these people a reduction in
18 spasticity or dystonia could have a negative impact on function. To ensure informed
19 decision-making, the risks and benefits of treatment should be discussed with each
20 person and specific treatment goals should be agreed.

21 There was limited evidence on treatments for spasticity and dystonia in adults with
22 cerebral palsy, but based on their experience and expertise the committee agreed on
23 a stepwise approach to treatment dependant on tolerability and effectiveness. This is
24 from the least invasive to the most invasive treatment option, which is reflected in the
25 order of recommendations in the individual sections:

- 26 • first identifying and managing any factors that might be exacerbating their
27 symptoms and considering a physical management programme
- 28 • next considering enteral (oral or via a feeding tube) drug treatment and referral
- 29 • then considering more invasive options.

1 **How the recommendations might affect practice**

2 The recommendations reflect current good practice.

3 Full details of the evidence and the committee's discussion are in [evidence review](#)
4 [A1: pharmacological treatments for spasticity](#) and [evidence review A3: interventions](#)
5 [for dystonia](#).

6 [Return to recommendations](#)

7 ***Drug treatments for spasticity***

8 Recommendations [1.3.6 to 1.3.11](#)

9 **Why the committee made the recommendations**

10 ***Enteral muscle relaxant drug treatments***

11 No evidence was identified on using enteral baclofen for treating spasticity in adults
12 with cerebral palsy. However, the committee discussed the evidence reviewed for
13 NICE's guideline on [spasticity in under 19s](#), and agreed that this could be
14 extrapolated to the adult population. There was limited evidence of effectiveness in
15 children and young people, but the committee agreed that it was sufficient,
16 supported by their experience, for enteral baclofen to be considered as a first-line
17 treatment for generalised spasticity causing functional impairment, pain or spasms.

18 The evidence on enteral diazepam showed no improvement in muscle tone, and side
19 effects such as drowsiness, vomiting and abdominal pain were recorded. The
20 committee agreed that it should not be offered routinely to treat spasticity because of
21 the risk of adverse events and also of dependency. However, evidence from NICE's
22 guideline on spasticity in children and young people and the committee's experience
23 suggested that diazepam can be beneficial in the short-term management of pain
24 and anxiety in acute situations.

25 There was no evidence for any other medicines. However, based on their experience
26 of current practice, the committee acknowledged that alternative drug treatments are
27 available that might be beneficial for some people if enteral baclofen is ineffective or
28 not tolerated. The committee agreed that in these situations specialist advice or
29 referral to specialist services is warranted to consider further treatment options.

1 Severe symptoms, such as life-threatening seizures, are associated with rapid
2 withdrawal of enteral muscle relaxants, so the committee highlighted the importance
3 of gradual withdrawal of these treatments.

4 ***Botulinum toxin type A injections***

5 There was some evidence that botulinum toxin type A injections improved muscle
6 tone in adults with cerebral palsy and spasticity. However, the evidence was limited,
7 and this treatment is more invasive and costly than alternative muscle relaxant drug
8 treatment. For these reasons, the committee agreed that it should only be
9 considered for people with focal spasticity and difficulties with their symptoms, who
10 might gain the most benefit from the treatment, or if a specialist agrees that it is likely
11 to be of benefit.

12 The committee discussed that botulinum toxin type A injections should be given by
13 an experienced specialist. This is important because the injections need to be
14 accurately placed for successful treatment and to avoid side effects. They
15 acknowledged that some healthcare professionals use ultrasound, electrical
16 stimulation or electromyography to help guide the injections, but noted that the
17 benefits and cost effectiveness of these techniques are uncertain. Additional
18 resources are associated with these techniques; for equipment and training, and for
19 an ultrasonographer or radiologist for ultrasound-guided injections. Therefore, the
20 committee developed a research recommendation to help determine the most
21 effective method for ensuring accurate positioning of these injections.

22 **How the recommendations might affect practice**

23 Overall, the recommendations reflect current good practice and will help to eliminate
24 variation, particularly in referrals to tone or spasticity management services.

25 The recommendation to consider enteral baclofen as a first-line option to manage
26 spasticity should not lead to a large increase in costs as enteral baclofen is relatively
27 cheap and is already widely used as a first-line option. Despite this, the committee
28 were unable to make a stronger recommendation because there was no comparative
29 clinical evidence that baclofen was the most effective option.

1 There was clinical evidence to suggest the cost of botulinum toxin could be
2 outweighed by its benefits when treating focal spasticity. The focus on referral for
3 focal spasticity that is causing pain, impacting care, or impairing activity is likely to
4 reduce the number of inappropriate referrals.

5 Any additional costs of specialist input is expected to be balanced by a reduction in
6 potentially inappropriate treatment and related adverse effects. There may be a
7 change to practice because enteral diazepam will no longer be prescribed routinely,
8 and this may result in a small cost saving.

9 Full details of the evidence and the committee's discussion are in [evidence review](#)
10 [A1: pharmacological treatments for spasticity](#).

11 [Return to recommendations](#)

12 ***Neurosurgical treatments to reduce spasticity***

13 Recommendations [1.3.12 to 1.3.17](#)

14 **Why the committee made the recommendations**

15 There was some limited evidence with high uncertainty suggesting that both
16 intrathecal baclofen and selective dorsal rhizotomy are effective in reducing muscle
17 tone in adults with spasticity. However, there are risks involved, both in having
18 surgery and of long-term complications. The committee highlighted the importance of
19 discussing the procedure with the person and their family or carers, so that they fully
20 understand what the treatment involves and the potential risks and benefits.

21 ***Intrathecal baclofen***

22 Using the evidence and their experience of current practice, the committee agreed
23 that intrathecal baclofen pumps can be beneficial for treating spasticity in some
24 adults with cerebral palsy. However, they should only be considered by a specialist
25 service that can safely carry out the procedure and has the expertise to assess
26 whether it is a suitable treatment for the person. There are potential risks of
27 intrathecal baclofen pump treatment. these include infections, catheter breakage,
28 seizures, constipation and anxiety or depression. After selective dorsal rhizotomy
29 there may be a deterioration in walking ability or bladder function, and later spinal

1 deformity. Taking into account these factors, the committee agreed that referral
2 should only be considered if a person still has difficulties with spasticity after trying
3 enteral muscle relaxant drug treatment or botulinum toxin type A injections. Due to
4 the complex nature of this procedure the committee noted that the adult with cerebral
5 palsy will need sufficient information to make an informed choice and that this is not
6 always consistently provided. A number of issues should be considered when
7 providing information specifically related to this surgical procedure, such as the need
8 for a test dose preimplantation, requirement of pump refill and regular follow-ups, the
9 details of what the surgical procedure involves, and a review of their 24 hour postural
10 needs.

11 The committee recognised that the response to intrathecal baclofen needs to be
12 tested before the pump would be implanted. They therefore highlighted a couple of
13 particular points about how the test dose (or doses if the person does not respond to
14 the initial test dose) would be administered. The committee did not want to be too
15 detailed about dosage and how the testing would be carried out because this is
16 described in the British National Formulary ([BNF](#)). The response should then be
17 assessed and discussed with the adult with cerebral palsy to ensure that a pump is
18 only implanted when a benefit is established in advance.

19 ***Selective dorsal rhizotomy***

20 The committee were aware that there is a risk of complications with selective dorsal
21 rhizotomy, including deterioration in walking ability and bladder function, and later
22 spinal deformity. Because of this and the limited evidence, the committee also took
23 into account NICE's interventional procedures guidance on [selective dorsal](#)
24 [rhizotomy for spasticity in cerebral palsy](#), published in 2010. Although they noted that
25 the evidence for the interventional procedure guidance was mostly in children. The
26 committee agreed that selective dorsal rhizotomy should only be considered after
27 multidisciplinary assessment in a specialist spasticity service, in line with the NICE
28 interventional procedures guidance.

29 The committee also recommended further research, comparing the safety and
30 effectiveness of selective dorsal rhizotomy with continuous intrathecal baclofen
31 pump treatment. Both procedures are currently used to treat spasticity in people with
32 cerebral palsy and there is some evidence that both are effective. However, the

1 committee noted that the procedures, and their risks and benefits, are very different.
2 They agreed that a comparative study would be helpful to inform decision-making.

3 **How the recommendations might affect practice**

4 The recommendations reinforce current best practice and should not lead to
5 additional resource use. Specialist services already exist and neurosurgical
6 procedures are currently available for the treatment of spasticity. Including specific
7 criteria for referral should reduce the number of inappropriate referrals to these
8 services.

9 Full details of the evidence and the committee's discussion are in [evidence review](#)
10 [A2: neurosurgical treatments for spasticity](#).

11 [Return to recommendations](#)

12 ***Drug treatments for dystonia***

13 Recommendations [1.3.18 to 1.3.22](#)

14 **Why the committee made the recommendations**

15 There was limited evidence on treating dystonia in adults with cerebral palsy. The
16 committee discussed that it is a specialist clinical area and that the benefits and
17 harms of treatments would need to be assessed by a person with expertise in tone
18 management. Therefore, the committee agreed that adults with cerebral palsy
19 should be referred for specialist management if they have problematic dystonia.

20 ***Enteral anti-dystonic drug treatments***

21 The evidence for levodopa was limited, although there was some evidence that it
22 was not effective for reducing dystonia in adults with severe impairment. Taking into
23 account the lack of evidence of effectiveness, and also the potential for side effects
24 and the cost of long-term treatment to the NHS, the committee agreed that levodopa
25 should not be prescribed routinely for dystonia in adults with cerebral palsy.

26 However, the committee agreed that a trial of levodopa can be useful to exclude the
27 rare but treatable condition of dopa-responsive dystonia.

28 No evidence was identified for other enteral anti-dystonic drug treatments. However,
29 based on their experience of current practice, the committee acknowledged that

1 there are other options available that might be beneficial for some people. They
2 agreed that first-line treatment options should depend on the person's symptoms and
3 treatment goals, and should only be considered by a specialist service.

4 ***Botulinum toxin type A injections***

5 No evidence was identified on using botulinum toxin type A injections for treating
6 dystonia in adults with cerebral palsy. However, based on their knowledge and
7 experience, the committee agreed that it can be of benefit to some people with focal
8 dystonia. Because there was no evidence and this treatment is more invasive and
9 costly than other enteral anti-dystonic drug treatments, the committee agreed that it
10 should only be considered under specialist supervision for people with focal dystonia
11 and difficulties with symptoms, who might gain the most benefit from the treatment.
12 They also agreed that it should only be used as part of a programme of therapy. This
13 would usually involve a physical management programme, for example, including
14 physiotherapy and splinting.

15 The committee emphasised that botulinum toxin type A injections should be given by
16 an experienced specialist. This is important because the injections need to be
17 accurately placed for successful treatment and to avoid side effects.

18 **How the recommendations might affect practice**

19 Overall, the recommendations reflect current good practice and will help to eliminate
20 variation, particularly in referral. There may be a change to practice because
21 levodopa will no longer be prescribed routinely, and this may result in a small cost
22 saving.

23 Full details of the evidence and the committee's discussion are in [evidence review](#)
24 [A3: neurosurgical treatments for spasticity](#).

25 [Return to recommendations](#)

26 ***Neurosurgical treatments to reduce dystonia***

27 Recommendations [1.3.23 to 1.3.24](#)

1 **Why the committee made the recommendations**

2 ***Intrathecal baclofen***

3 Despite a lack of evidence, the committee agreed that their knowledge and
4 experience of current practice supported the use of intrathecal baclofen pumps for
5 treating dystonia in some adults with cerebral palsy. However, they should only be
6 considered by a specialist service that can safely carry out the procedure and has
7 the expertise to assess whether it is a suitable treatment for the person. There are
8 potential risks of intrathecal baclofen pump treatment. These include infections,
9 catheter breakage, seizures, constipation and anxiety or depression. It is also more
10 costly than other drug treatments. Taking into account these factors, the committee
11 agreed that it should only be considered when a person still has difficulties with
12 dystonia after trying enteral anti-dystonic drug treatment or botulinum toxin type A
13 injections.

14 The committee also highlighted the importance of discussing the procedure with the
15 person and their family or carer, so that they fully understand what the treatment
16 involves and the potential risks and benefits.

17 The committee agreed that the same considerations about intrathecal baclofen
18 testing that have been made for spasticity also apply to dystonia and therefore cross
19 referenced to the relevant recommendations.

20 ***Deep brain stimulation***

21 Although there was limited and sometimes incongruous evidence for deep brain
22 stimulation, it did suggest some improvement in dystonia after treatment. However,
23 some complications were noted, including problems with speech, pain, numbness
24 and anxiety, as well as problems with the equipment. Deep brain stimulation is
25 expensive. Two studies identified as part economic evidence, suggested it would
26 improve quality of life. However, the economic evidence was inconsistent, showing
27 that it was likely to be cost effective in people with dystonia that has not improved
28 with other treatments when based on the outcomes of one quality of life study but not
29 cost effective using the other. The committee also took into account NICE's
30 interventional procedures guidance on [deep brain stimulation for tremor and dystonia](#)
31 [\(excluding Parkinson's disease\)](#) published in 2006, which supports its use with the

1 involvement of a multidisciplinary team. Based on the evidence on improvements in
2 quality of life and the committee's knowledge and experience, they agreed that deep
3 brain stimulation should only be considered for people who have severe and painful
4 dystonia, and only carried out at an experienced specialised centre.

5 **How the recommendations might affect practice**

6 Overall, the recommendations reflect current good practice and will help to eliminate
7 variation.

8 Full details of the evidence and the committee's discussion are in [evidence review](#)
9 [A3: neurosurgical treatments for spasticity](#).

10 [Return to recommendations](#)

11 ***Bone and joint disorders***

12 Recommendations [1.4.1 to 1.4.8](#)

13 **Why the committee made the recommendations**

14 Based on their experience, the committee noted that there is a lack of awareness,
15 both among adults with cerebral palsy and healthcare professionals, that people with
16 cerebral palsy are at increased risk of bone and joint complications, and that
17 musculoskeletal function may worsen over time. Common complications include
18 osteoporosis and conditions caused by abnormal musculoskeletal development,
19 such as scoliosis and subluxation of joints. Increasing awareness and discussing this
20 with adults with cerebral palsy will enable early identification and management of
21 these conditions.

22 ***Osteoporosis and fracture risk***

23 The committee agreed that assessing fracture risk is important for adults with
24 cerebral palsy who are at increased risk of osteoporosis to enable action to be taken
25 to manage osteoporosis and prevent fractures. Based on their experience and
26 knowledge the committee identified factors that are associated with increased risk
27 and agreed that fracture risk assessment should be considered for adults with
28 cerebral palsy with these factors. In addition to the risk factors related to cerebral
29 palsy (such as reduced weight bearing), risk factors for the general population also

1 apply. These are described in NICE's guideline on [osteoporosis: assessing the risk](#)
2 [of fragility fracture](#) along with information about assessing fracture risk.

3 There was some evidence that dual-energy X-ray absorptiometry (DXA) scanning
4 can be effective in identifying reduced bone density in adults with cerebral palsy.
5 However, the committee noted that these scans can often be uncomfortable and the
6 results difficult to interpret in people with cerebral palsy. The risks of treatment may
7 also outweigh the benefits in people without symptoms. For these reasons they
8 agreed that it should only be considered for people with more than 1 risk factor,
9 suggesting a high risk of fractures and osteoporosis.

10 Based on their experience, the committee agreed that assessment and management
11 of osteoporosis in adults with cerebral palsy is highly complex, and that referral to a
12 specialist service is often necessary. For some people this may be to a
13 rheumatology or bone health service, for others referral to endocrinology may be
14 considered to explore whether a hormonal condition could be affecting their bones.

15 ***Disorders caused by abnormal musculoskeletal development***

16 Adults with cerebral palsy may develop joint abnormalities due to problems of tone,
17 movement and posture. No evidence was identified on monitoring for these
18 disorders. However, the committee agreed that specialist referral is needed for
19 assessment and management if these conditions are suspected and causing
20 problematic symptoms. They highlighted some of the more common disorders to
21 help increase awareness and improve recognition.

22 The committee were aware that hip and spine X-rays may be offered routinely to
23 children and young people in paediatric services. However, ongoing surveillance is
24 not necessary for adults once growth is complete, and X-rays should not be offered
25 unless there are new problems of pain, posture or difficulties with care.

26 **How the recommendations might affect practice**

27 The recommendations for risk assessment and DXA scanning are unlikely to change
28 current practice. DXA scans should already be considered under NICE's guideline
29 on assessing the risk of fragility fracture.

1 The recommendations could increase referrals to specialist services. However, the
2 impact of this is likely to be balanced by better treatment and prevention of hospital
3 stays.

4 Full details of the evidence and the committee's discussion are in [evidence review](#)
5 [B1: disorders of bones and joints](#).

6 [Return to recommendations](#)

7 ***Mental health problems***

8 Recommendations [1.4.9 to 1.4.15](#)

9 **Why the committee made the recommendations**

10 No evidence was found on assessing and monitoring mental health in adults with
11 cerebral palsy. However, from their experience, the committee acknowledged that
12 healthcare services for adults with cerebral palsy tend to focus on physical rather
13 than mental health. Greater awareness of mental health problems and the specific
14 challenges of identifying and managing them in adults with cerebral palsy would help
15 to ensure that such problems are recognised and managed. Alongside this, the
16 committee highlighted that discussing the person's mental wellbeing at each review
17 would help to identify any concerns and ensure that support for mental health
18 problems is included in the person's care plan. Important insights about a person's
19 mental health can often be gained from people close to them, so the committee
20 agreed that (with consent from the person) family members or carers should also be
21 asked if they have any concerns.

22 Physical problems and common frustrations that can affect emotional wellbeing in
23 adults with cerebral palsy were highlighted by the committee because they are often
24 overlooked, but can negatively affect mental health and behaviour.

25 The committee noted that there are many relevant NICE guidelines related to mental
26 health conditions that would apply to adults with cerebral palsy, and other NICE
27 guidelines relevant to those with communication difficulties or learning disabilities.

28 **How the recommendations might affect practice**

29 The recommendations will reinforce current best practice.

1 Full details of the evidence and the committee's discussion are [in evidence review](#)
2 [B2: monitoring and assessing mental health](#).

3 [Return to recommendations](#)

4 ***Difficulties with eating and nutritional problems***

5 Recommendations [1.4.16 to 1.4.21](#)

6 **Why the committee made the recommendations**

7 There was some evidence on tools for assessing nutritional status in adults with
8 cerebral palsy, but the committee concluded that the evidence was not good enough
9 to recommend a specific tool. In addition, many factors can affect feeding and
10 nutrition, so they agreed that a single tool is unlikely to be suitable for everyone.

11 Based on their experience, the committee agreed that assessment should be
12 individualised to reflect each adult's needs and circumstances. Current good practice
13 includes regular weight and BMI checks, and talking to the person and their families
14 and carers about feeding behaviour and other factors affecting feeding and weight.
15 People identified as at risk of undernutrition or with eating difficulties can then be
16 referred to a specialist to assess for and treat specific feeding or nutrition problems.
17 Because the recommendations focus on individualised assessment, the committee
18 agreed that specific tools for assessing nutrition are not a priority for further
19 research.

20 The committee discussed the role of people caring for adults with cerebral palsy and
21 agreed that training should be provided in line with the NICE guideline on [nutrition](#)
22 [support for adults](#), to help pick up any problems between reviews.

23 The committee noted that adults with dyskinetic cerebral palsy or severe spasticity
24 may have an increased metabolic rate and need to increase their calorie intake to
25 prevent malnutrition. The committee recognised that reduction in dyskinesia or
26 spasticity by treatment such as intrathecal baclofen may result in weight gain. They
27 agreed that, from their experience, this can go unrecognised and that greater
28 awareness could help people get the support they need.

1 **How the recommendations might affect practice**

2 The recommendations will reinforce current best practice.

3 Full details of the evidence and the committee's discussion are in [evidence review](#)

4 [B3: monitoring feeding and nutritional problems](#).

5 [Return to recommendations](#)

6 ***Identifying and monitoring respiratory disorders***

7 Recommendations [1.4.22 to 1.4.25](#)

8 **Why the committee made the recommendations**

9 No evidence was found on monitoring respiratory health in adults with cerebral palsy.
10 Adults with cerebral palsy are at an increased risk of respiratory failure, which can be
11 life-threatening. However, based on their experience and knowledge, the committee
12 agreed that the early symptoms of respiratory impairment may sometimes go
13 unrecognised. Greater awareness and earlier recognition and treatment may result
14 in treatment that prevents progression to respiratory failure.

15 Based on their experience and some limited evidence, the committee agreed that
16 better awareness of the risk factors for respiratory impairment would help to ensure
17 early recognition and appropriate referral. They also wanted to highlight that these
18 are more common in adults with severe impairment, such as a high Gross Motor
19 Function Classification System (GMFCS) score. They agreed that referral for
20 specialist assessment would enable prevention or treatment of respiratory
21 complications in people at high-risk.

22 The committee discussed that reduced lung volume is an important factor
23 contributing to respiratory impairment. However, there was limited evidence available
24 on the value of spirometry in assessing respiratory function in adults with cerebral
25 palsy. Based on their experience and expertise, the committee agreed that
26 spirometry should be considered for people at high risk of respiratory impairment to
27 help identify people who may need treatment.

28 The committee agreed that further research on identifying respiratory impairment in
29 adults with cerebral palsy would be helpful. They developed a research

1 recommendation to determine the most effective methods of detecting and managing
2 respiratory impairment in the community.

3 **How the recommendations might affect practice**

4 Better survival of children with cerebral palsy into adulthood means that this is an
5 emerging area of practice. There are relatively few respiratory specialists with a
6 special interest in adults with cerebral palsy. There may be an increase in referrals,
7 which might place increased pressure on limited specialist services. However, earlier
8 recognition and treatment will lead to improved outcomes. Respiratory conditions
9 can often lead to hospital admission and reducing the need for this would potentially
10 lead to cost savings.

11 Full details of the evidence and the committee's discussion are in [evidence review](#)
12 [C1: protocols for monitoring respiratory health](#).

13 [Return to recommendations](#)

14 ***Prophylactic treatments for respiratory infections***

15 Recommendations [1.4.26 to 1.4.30](#)

16 **Why the committee made the recommendations**

17 No evidence was identified on preventing respiratory infections in adults with
18 cerebral palsy. The committee agreed that adults with cerebral palsy and their carers
19 should receive vaccinations in line with national guidance from the government, as
20 set out in the [Green book \(this could for example be the flu vaccination\)](#).

21 Applying their clinical expertise and experience, the committee agreed that the role
22 of antibiotics is limited for prophylaxis of respiratory infections in adults with cerebral
23 palsy. Taking into account potential adverse effects and the principles of antibiotic
24 stewardship, the committee agreed that antibiotic prophylaxis should only be used in
25 people at high risk of infection when it is advised by the respiratory specialist. For
26 example, this might be in people with recurrent chest infections and bacterial
27 colonisation identified on sputum culture. The aim in these cases would be to reduce
28 acute antibiotic use and limit symptom burden.

1 The committee agreed that the prevention of respiratory infections is an important
2 area for research. Many people with cerebral palsy have respiratory symptoms
3 caused by sputum retention or recurrent respiratory infection, possibly related to
4 aspiration. A smaller number have chronic bacterial airway colonisation with
5 increased respiratory symptom burden and recurrent infections. The committee
6 developed a research recommendation to determine the role of prophylactic
7 antibiotics in those with, and without, persistent bacterial airway colonisation with,
8 the aim of improving their quality of life and preventing hospital stays.

9 Although, there was no evidence for chest physiotherapy to prevent respiratory
10 infections, the committee discussed the potential benefits of postural management
11 and exercise. Based on their experience and expertise, they agreed that a
12 physiotherapy chest care review should be considered for adults with cerebral palsy
13 who are at high risk of respiratory infection. The committee also noted that families
14 and carers can help with ongoing chest care, but may not always receive adequate
15 support to enable this. They agreed that it would be beneficial for this to be included
16 as part of the chest care review. This could include advice on posture, position
17 change, opportunities to move, interventions to assist ventilation and secretion
18 control management.

19 Effective swallowing (and saliva control) is important to prevent respiratory infections
20 in adults with cerebral palsy. The committee agreed that assessment by a
21 dysphagia-trained speech and language therapist should be considered for people
22 with recurrent chest infections that may be caused by dysphagia.

23 **How the recommendations might affect practice**

24 The recommendations on vaccination reinforce current best practice.

25 Referral to a respiratory team for adults with cerebral palsy will reinforce best
26 practice. However, there may be an increase in referrals, which could put additional
27 pressure on already limited specialist services.

28 The recommendation on prophylactic antibiotic use is not considered to be a change
29 in practice. However, there may be a small decrease in use of prophylactic
30 antibiotics, which could lead to cost savings.

1 The recommendations on chest physiotherapy review and referral to dysphagia-
2 trained speech and language therapist are unlikely to have a big impact on current
3 practice. There may be a small increase in the number of referrals. This is likely to
4 be balanced by improved prevention of respiratory infections. There may also be an
5 increase in provision of training and support for families and carers. However, this is
6 likely to be balanced by improved ongoing chest care which would reduce respiratory
7 infections and the costs associated with them.

8 Full details of the evidence and the committee's discussion are in [evidence review](#)
9 [C3: prophylactic treatments for respiratory disorders](#).

10 [Return to recommendations](#)

11 ***Discussing the management of respiratory failure, and assisted*** 12 ***ventilation for respiratory failure and sleep apnoea***

13 Recommendations [1.4.30 to 1.4.36](#)

14 **Why the committee made the recommendations**

15 The management of respiratory failure varies according to individual circumstances
16 and preferences. The committee noted that having discussions about the
17 effectiveness and tolerability of treatments (for example, non-invasive ventilation can
18 be uncomfortable), as well as planning for future treatment and what to do if their
19 condition worsens, helps to identify the most appropriate treatment pathway.

20 Although no evidence was identified on assisted ventilation for adults with cerebral
21 palsy, the committee noted that there is evidence supporting non-invasive ventilation
22 in people with progressive neuromuscular conditions. The committee discussed that
23 the course and symptoms of respiratory failure may be similar across the different
24 conditions. They agreed that non-invasive ventilation could be beneficial, based on
25 evidence extrapolated from these populations and the committee's experience. The
26 committee also agreed that it is important to review management every 3–6 months,
27 which is consistent with standard practice.

28 The committee discussed that people's goals and preferences for management after
29 acute deterioration in respiratory function will vary. Based on their experience and

1 expertise, the committee highlighted the importance of agreeing a management plan
2 with the person (and their family or carers, if agreed) for future care in this situation.
3 This should be documented in the person's advance care plan. A full understanding
4 of the options available and the person's values, preferences and goals will lead to
5 better shared decision-making and more informed choices about care.

6 Based on their experience and expertise, the committee discussed that when
7 treatment goals are not met by non-invasive techniques, alternative options like
8 tracheostomy or supportive care could be considered. There was no evidence
9 available in adults with cerebral palsy, but the committee agreed that tracheostomy
10 can be effective for some patients in maintaining quality of life.

11 The committee recognised that sleep apnoea is common in adults with cerebral
12 palsy. It can affect sleep quality and therefore quality of life. They agreed that
13 treatment would be the same for adults with cerebral palsy as in the general
14 population and cross-referred to the NICE technology appraisal guidance on
15 [continuous positive airway pressure for the treatment of obstructive sleep](#)
16 [apnoea/hypopnoea syndrome](#).

17 **How the recommendations might affect practice**

18 The recommendations in this section reinforce the current best practice and will help
19 to standardise practice.

20 Full details of the evidence and the committee's discussion are in [evidence review](#)
21 [C2: assisted ventilation for respiratory failure](#).

22 [Return to recommendations](#)

23 ***Pain***

24 Recommendations [1.4.36 to 1.4.39](#)

25 **Why the committee made the recommendations**

26 The committee agreed that it can be difficult to recognise pain in people with
27 communication difficulties. They agreed that better awareness of this would help to
28 prevent under-identification of pain.

1 The evidence indicated that for adults with cerebral palsy who are able to
2 communicate the numerical, visual analogue and faces pain scales had similarly
3 good reliability and validity. Although the use of body maps was not evaluated in the
4 evidence, the committee agreed they would also be a useful way to help localise the
5 source of any pain. The committee acknowledge that families and carers have
6 valuable insight into the best ways to tell whether an individual was experiencing
7 pain, and this is especially important if the person has communication difficulties. For
8 adults with cerebral palsy who are unable to communicate, the committee agreed
9 that observational and descriptive pain scales would be appropriate and useful. The
10 committee agreed that in practice the method chosen would depend on the person's
11 individual needs and circumstances, in particular, their ability to communicate.

12 The committee highlighted that signs of distress from pain may sometimes be
13 mistaken for other symptoms. By improving awareness of pain and highlighting the
14 role of families and carers in recognising pain the committee aim to reduce the
15 under-identification of pain.

16 The committee were also aware that people caring for adults with cerebral palsy do
17 not always have access to suitable pain assessment tools or the training that is
18 needed for their use. Based on their experience, they agreed that these are
19 important to enable pain to be recognised, localised pain identified and treatment
20 targeted effectively.

21 **How the recommendations might affect practice**

22 The recommendations reflect the current practice of selecting an appropriate
23 measure from a range of pain assessment methods, depending on the person's
24 ability to communicate. The committee acknowledged that although learning
25 disability nurses currently train carers in generic pain assessment techniques,
26 individualised training and documentation of how best to identify pain in the care plan
27 would be a change in practice in some centres and may have a cost impact.

28 Full details of the evidence and the committee's discussion are in [evidence review E:
29 Identifying pain, such as musculoskeletal and gastrointestinal pain](#).

30 [Return to recommendations](#)

1 **Context**

2 Cerebral palsy is a disorder of motor development caused by a non-progressive
3 pathology that affects the developing brain. People with cerebral palsy may also
4 have disorders of communication, learning, feeding and vision, and epilepsy.
5 Cerebral palsy is a lifelong condition and there is not yet a cure for the underlying
6 brain disorder.

7 There are now more adults living with cerebral palsy than there are children with
8 cerebral palsy. Adults with cerebral palsy have a wide range of abilities – from full
9 independence in everyday life to needing 24-hour care and attention.

10 New interventions are coming into routine clinical practice for the management of
11 premature babies and babies in a poor condition at birth who are at high risk of
12 developing cerebral palsy. These may change the pattern of cerebral palsy and its
13 related comorbidities. With improved survival, more children with severe and
14 complex cerebral palsy are likely to live beyond childhood and into adult life. As they
15 become young adults and transfer into adult services this group will continue to need
16 regular monitoring of their health and wellbeing.

17 Adults with cerebral palsy should be able to become as functionally independent as
18 possible. Many may wish to go into further education, gain employment, participate
19 in leisure activities and contribute fully to society. Barriers to these goals should be
20 minimised so that adults with cerebral palsy have equal access to all opportunities.

21 Adults with cerebral palsy tend to have less fluctuation in their motor skills than
22 children. However, their mobility may decrease because of factors, such as muscle
23 tone, weakness and pain. Comorbid symptoms, such as pain, mental health
24 problems, communication difficulties and nutritional problems can, individually and in
25 combination, affect participation and quality of life. These should also be a high
26 priority for management.

27 As adults with cerebral palsy who have ongoing care needs grow older, there may
28 be changes in their care arrangements. It may not be possible for their parents to
29 continue to be the main carers and other support may be needed, either in the

1 community or a residential setting. There is always the need for ongoing training and
2 support for those who are caring for adults with cerebral palsy.

3 The care and support needs of adults with cerebral palsy depend on the severity of
4 impairment and the presence or absence of comorbidities. There is significant
5 variation in how services are currently provided to meet these needs. However, there
6 is not a single system appropriate for all adults with cerebral palsy. In line with the
7 [Equality Act 2010](#) and the [UN Convention on the rights of persons with disabilities](#),
8 this guideline aims to ensure that adults with cerebral palsy have easy access to
9 equitable, cost-efficient services, with a clear network of referral to more specialised
10 services as appropriate.

11 **Finding more information and resources**

12 To find out what NICE has said on topics related to this guideline, see our web
13 pages on [cerebral palsy](#) and [spasticity](#).

14 © NICE 2018. All rights reserved. Subject to [Notice of rights](#).